Relevant bibliographies by topics / Resistance to therapies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Resistance to therapies'

Author: Grafiati
Published: 16 November 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Resistance to therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Resistance to therapies"

1

Gupta, P. D. "Reducing drug resistance should be the aim of therapies." Clinical Research and Clinical Trials 3, no. 4 (2021): 01–05. http://dx.doi.org/10.31579/2693-4779/028.

Full text
Abstract:
Over the period, due to evolutionary constrains, gene mutations, changes in micro- and mega- environment gave a tool to bacteria to adopt for survival in the hostile environment. When they are exposed with broad spectrum antibiotics, they have adopted to live and become resistant to antibiotics. In this review many preventive and curative strategies has been described to avoid antibiotics. These lines of treatments would not give chances to microbes to become drug resistant. “Prevention is better than cure” adopting this strategy we have described immunochemicals and many herbal medicines whic
APA, Harvard, Vancouver, ISO, and other styles
2

Bartolotti, Marco, Enrico Franceschi, Rosalba Poggi, Alicia Tosoni, Monica Di Battista, and Alba A. Brandes. "Resistance to antiangiogenic therapies." Future Oncology 10, no. 8 (2014): 1417–25. http://dx.doi.org/10.2217/fon.14.57.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Prasad, Rajendra, Atanu Banerjee, and Abdul Haseeb Shah. "Resistance to antifungal therapies." Essays in Biochemistry 61, no. 1 (2017): 157–66. http://dx.doi.org/10.1042/ebc20160067.

Full text
Abstract:
The evolution of antifungal resistance among fungal pathogens has rendered the limited arsenal of antifungal drugs futile. Considering the recent rise in the number of nosocomial fungal infections in immunocompromised patients, the emerging clinical multidrug resistance (MDR) has become a matter of grave concern for medical professionals. Despite advances in therapeutic interventions, it has not yet been possible to devise convincing strategies to combat antifungal resistance. Comprehensive understanding of the molecular mechanisms of antifungal resistance is essential for identification of no
APA, Harvard, Vancouver, ISO, and other styles
4

Tejpar, Sabine, Hans Prenen, and Massimiliano Mazzone. "Overcoming Resistance to Antiangiogenic Therapies." Oncologist 17, no. 8 (2012): 1039–50. http://dx.doi.org/10.1634/theoncologist.2012-0068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sledge, George W. "Resistance to Anti-HER2 Therapies." Breast 20 (October 2011): S16. http://dx.doi.org/10.1016/j.breast.2011.08.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lawrence Drew, W. "Cytomegalovirus resistance to antiviral therapies." American Journal of Health-System Pharmacy 53, suppl_2 (1996): S17—S23. http://dx.doi.org/10.1093/ajhp/53.8_suppl_2.s17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thangavadivel, Shanmugapriya, and Jennifer A. Woyach. "Genomics of Resistance to Targeted Therapies." Hematology/Oncology Clinics of North America 35, no. 4 (2021): 715–24. http://dx.doi.org/10.1016/j.hoc.2021.03.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Guièze, Romain. "Mechanisms of resistance to targeted therapies." Hématologie 26, S3 (2020): 20–26. http://dx.doi.org/10.1684/hma.2020.1564.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fong, Chun Yew, Omer Gilan, Enid Lam, et al. "Modelling Resistance to Emerging Epigenetic Therapies." Blood 124, no. 21 (2014): 3546. http://dx.doi.org/10.1182/blood.v124.21.3546.3546.

Full text
Abstract:
Abstract The BET inhibitors are first-in-class, epigenetic targeted therapies that deliver a new therapeutic paradigm by directly targeting protein-protein interactions at chromatin. Early clinical trials have shown significant promise, especially in AML, suggesting that these compounds are likely to form an important component of future anti-cancer regimens. Therapeutic resistance is an inevitable consequence of most cancer therapies, therefore the evaluation of resistance mechanisms is of utmost importance in order to optimize the clinical utility of this novel class of drugs. Using primary
APA, Harvard, Vancouver, ISO, and other styles
10

Smith, Sinéad M., Colm O’Morain, and Deirdre McNamara. "Helicobacter pylori resistance to current therapies." Current Opinion in Gastroenterology 35, no. 1 (2019): 6–13. http://dx.doi.org/10.1097/mog.0000000000000497.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Resistance to therapies"

1

Hewlett, Mark. "The evolution of resistance to multidrug antibiotic therapies." Thesis, University of Exeter, 2015. http://hdl.handle.net/10871/21596.

Full text
Abstract:
The purpose of this thesis is to explore the interaction between antibiotics at sub-lethal doses, and E.coli. Initially we focussed on pairwise antibiotic interaction, and the potential to exploit these interactions to minimise antibiotic resistance. In testing the hypothesis that antagonism will slow adaptation by reducing selection for resistance we determined that there are conditions in which this fails to be the case. We furthermore caution against treating drug interactions as anything other than a dynamic property of the bacteria-drug interaction, by showing that the relationship betwee
APA, Harvard, Vancouver, ISO, and other styles
2

Guix, Arnau Marta 1974. "Mechanisms of acquired resistance to anti-EGFR therapies in squamous cell carcinoma." Doctoral thesis, Universitat Pompeu Fabra, 2017. http://hdl.handle.net/10803/565440.

Full text
Abstract:
Targeted therapies against the Epidermal Growth Factor Receptor (EGFR) are useful to treat many human cancers such as non-small cell lung cancer, colorectal cancer and head and neck cancer. However, the efficacy of such treatments is always compromised by resistance. This doctoral thesis has focused in the mechanisms of acquired resistance to targeted therapies against the EGFR (such as the small tyrosine kinase inhibitors gefitinib and erlotinib, or the monoclonal antibody cetuximab) in squamous cell carcinomas. In the first part of the thesis, preclinical studies with cellular and xenograft
APA, Harvard, Vancouver, ISO, and other styles
3

McGivern, Niamh. "Activation of MAPK signalling results in resistance to therapies for ovarian cancer." Thesis, Queen's University Belfast, 2015. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.695671.

Full text
Abstract:
Ovarian cancer is the fifth most common cancer affecting women in the UK, and is the most lethal of all gynaecological cancers. Treatment primarily consists of debulking surgery followed by a platinum and taxane based chemotherapy, and despite initial high levels of response, the majority of women will relapse with platinum resistant disease, resulting in a poor prognosis. Few targeted therapies have entered the clinic for the treatment of ovarian cancer, however there is strong preclinical data to suggest there is a therapeutic window to target SRC tyrosine kinase in this disease. The SAPPROC
APA, Harvard, Vancouver, ISO, and other styles
4

Sun, Xiaowen. "An integrin-based mechanism for sensitizing melanomas to therapies." Diss., University of Iowa, 2015. https://ir.uiowa.edu/etd/6506.

Full text
Abstract:
Metastatic melanoma is unusually lethal with a ten year survival rate of less than 10%. Conventional DNA-damaging agents produce little improvement in patient survival. Vemurafenib (Zelboraf), a targeted therapeutic that inhibits the oncogenic BRAF demonstrates significant survival benefit. Unfortunately, it is now evident that there is both intrinsic and acquired resistance. Consequently, new strategies for sensitizing melanomas to vemurafenib are needed. Melanoma resistance to therapy is fueled in part by the integrins, the major cell surface adhesion receptors which are highly over-expresse
APA, Harvard, Vancouver, ISO, and other styles
5

Neto, João Manuel Fernandes. "Improvement of antiangiogenic therapies in colorectal cancer." Master's thesis, Universidade de Aveiro, 2015. http://hdl.handle.net/10773/15349.

Full text
Abstract:
Mestrado em Biotecnologia – Biotecnologia Industrial e Ambiental<br>Angiogenesis is essential for tumor progression. Antiangiogenic therapies block angiogenesis and cause vessel regression, which leads to an increase of tumor hypoxia. Hypoxia is responsible for many effects in tumor biology, among which, the selection of cells that are more aggressive and more resistant to cancer therapies. In this project we aim to get some molecular insight on the mechanism(s) underlying the resistance to the combination of bevacizumab and cetuximab and to find synthetic lethal interactions with hypoxia. O
APA, Harvard, Vancouver, ISO, and other styles
6

Phee, Lynette. "Unorthodox antimicrobial combination therapies for the treatment of multi-drug resistant Gram-negative infections." Thesis, Queen Mary, University of London, 2018. http://qmro.qmul.ac.uk/xmlui/handle/123456789/44695.

Full text
Abstract:
The rise of antimicrobial resistance (AMR) has culminated in the most pressing problem in modern medicine. The situation is most acute with regards to the management of multi- drug resistant Gram-negative infections (MDRGNB) with common infections increasingly untreatable due to rapidly dwindling therapeutic options. A solution to the problem of AMR is unlikely to be easily found, but revisiting and re-purposing existing antimicrobials is a viable approach in the medium term. This study investigated the use of unorthodox antimicrobial combination therapies for the treatment of MDRGNB, with par
APA, Harvard, Vancouver, ISO, and other styles
7

Cerqueira, Vera. "Role of intracellular signalling pathways in conferring resistance to endocrine therapies in breast cancer." Thesis, University of Edinburgh, 2010. http://hdl.handle.net/1842/4511.

Full text
Abstract:
Breast cancer is the most prevalent form of cancer in women and accounts for 519,000 annual deaths (WHO Statistics). It has long been established that oestrogen (E2) stimulates tumour growth of oestrogen receptor (ER) positive breast cancer and is involved in the pathogenesis of the disease. Consequently, therapeutic approaches targeting the ER were developed. The use of endocrine therapy is an integral component in treating breast cancer however resistance to such drugs is a major limitation. Unfortunately, even initially responding tumours eventually develop resistance - acquired resistance.
APA, Harvard, Vancouver, ISO, and other styles
8

Yeoman, Kathryn (Kate) Charlotte. "Working the System: Doing Postmodern Therapies in Aotearoa New Zealand." Thesis, University of Canterbury. Humanities, 2012. http://hdl.handle.net/10092/7274.

Full text
Abstract:
This thesis documents a qualitative research study of twenty postmodern therapy practitioners in Aotearoa New Zealand, focusing on their experiences in the wider field of therapy. The participants were aligned in their subscribing to postmodern critiques of therapy as a instrument of power, and in their interest in, and use of, therapy techniques and approaches that have grown out of those critiques – including narrative therapy, critical psychology, “Just Therapy”, and feminist poststructuralist therapy approaches. I argue that these practitioners represent a social movement within the field
APA, Harvard, Vancouver, ISO, and other styles
9

Söderhäll, Thomas. "Antibiotic combination therapies against carbapenamse producing Klebsiella pneumoniae." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-452424.

Full text
Abstract:
The treatment options for multidrug resistant bacteria are dwindling and it is an important issue of research in medicine to solve. One of the more problematic bacterial species is Klebsiella pneumoniae, it can cause infections with high morbidity that are difficult to treat. Common antibiotics for treatment of these infections are carbapenems but K. pneumoniae can produce enzymes called carbapenemases that can hydrolyze carbapenems and most other beta-lactam antibiotics. In this study carbapenemase genes were introduced chromosomally to a previously susceptible K. pneumoniae strain using λ-Re
APA, Harvard, Vancouver, ISO, and other styles
10

Salazar, Marcela d'Alincourt. "Genomic Effects of Hormonal Adjuvant Therapies that Could Support the Emergence of Drug Resistance in Breast Cancer." University of Toledo Health Science Campus / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=mco1280929084.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Resistance to therapies"

1

Xavier, Ana C., and Mitchell S. Cairo, eds. Resistance to Targeted Therapies in Lymphomas. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24424-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ling, Silvia CW, and Steven Trieu, eds. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73440-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Villanueva, Augusto, ed. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56197-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Prosperi, Jenifer R., ed. Resistance to Targeted Therapies in Breast Cancer. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70142-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tivnan, Amanda, ed. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46505-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Szewczuk, Myron R., Bessi Qorri, and Manpreet Sambi, eds. Current Applications for Overcoming Resistance to Targeted Therapies. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ferreri, Andrés J. M., ed. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75184-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Scardino, Peter T. Targeted Therapies for Castration-Resistant Prostate Cancer. Future Medicine Ltd, 2011. http://dx.doi.org/10.2217/9781780840109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Michael, Neenan, ed. Working with resistance in rational emotive behaviour therapy: A practitioner's guide. Routledge, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Resistance to therapies"

1

Weber, Georg F. "Drug Resistance." In Molecular Therapies of Cancer. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13278-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

McEwan, Ashley, and Silvia CW Ling. "Bone Targeted Therapies." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73440-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pepper, John W. "Somatic Evolution of Acquired Drug Resistance in Cancer." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kroll, David S. "Treatment Resistance and Advanced Therapies." In Caring for Patients with Depression in Primary Care. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08495-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Qadri, Hafsa, Manzoor Ahmad Mir, and Abdul Haseeb Shah. "Antifungal Therapies and Drug Resistance." In Human Fungal Diseases. CRC Press, 2024. http://dx.doi.org/10.1201/9781032642864-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dai, Yun, and Steven Grant. "Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lage, Hermann, and Carsten Denkert. "Resistance to Chemotherapy in Ovarian Carcinoma." In Targeted Therapies in Cancer. Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-46091-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lyons, Anna T., and Jenifer R. Prosperi. "Targeted Therapies in Breast Cancer." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70142-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gunther, Edward. "Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Srivastava, Rupali, Ananya Padmakumar, Paloma Patra, Sushma V. Mudigunda, and Aravind Kumar Rengan. "Phytonanotechnologies for Addressing Antimicrobial Resistance." In Medicinal Plants and Antimicrobial Therapies. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-7261-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Resistance to therapies"

1

Brugge, JS, T. Muranen, J. Zoeller, et al. "DL1-1: Adaptive Resistance to Targeted Therapies." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-dl1-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Zhenghong, Carrie Qi Sun, Rebecca Arnold, John A. Petros, and Carlos S. Moreno. "Abstract 284: Combination therapies to prevent resistance to androgen deprivation therapies in prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-284.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Zhenghong, Carrie Qi Sun, Rebecca Arnold, John A. Petros, and Carlos S. Moreno. "Abstract 284: Combination therapies to prevent resistance to androgen deprivation therapies in prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-284.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Baolin, Junjie Chen, Xu Di, and Yaqin Zhang. "Abstract B246: Overcoming cancer resistance to death receptor targeted therapies." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-b246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brown, Wells S., and Michael Wendt. "Abstract B49: Epithelial-mesenchymal plasticity primes inherent resistance to targeted therapies." In Abstracts: AACR Special Conference on Tumor Metastasis; November 30-December 3, 2015; Austin, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tummet15-b49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Luna, Augustin, Özgün Babur, Gonghong Yan, Emek Demir, Chris Sander, and Anil Korkut. "Abstract 2838: Discovery of adaptive resistance pathways and anti-resistance combination therapies in cancer from phosphoproteomic data." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2838.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Montero, Joan, Cecile Gstalder, Daniel J. Kim, et al. "Abstract 62: Destabilization ofNOXAmRNA as a common resistance mechanism to targeted therapies." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zamanian, Roham T., Mehdi Skhiri, Andrew Hsi, vinicio de Jesus Perez, and Francois Haddad. "Impact Of PAH Specific Therapies On Insulin Resistance In Pulmonary Arterial Hypertension." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5919.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Politi, Katerina A. "Abstract IA10: Modeling sensitivity and resistance to systemic therapies in lung cancer." In Abstracts: AACR Special Conference on the Evolving Landscape of Cancer Modeling; March 2-5, 2020; San Diego, CA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.camodels2020-ia10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Luna, Augustin, Heping Wang, Ozgun Babur, Chris Sander, and Anil Korkut. "Abstract 3820: Discovery of adaptive resistance pathways and anti-resistance combination therapies from phosphoproteomic data using graphical models." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3820.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Resistance to therapies"

1

Li, wanlin, jie Yun, siying He, ziqi Zhou, and ling He. Effect of different exercise therapies on fatigue in maintenance hemodialysis patients:A Bayesian Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0144.

Full text
Abstract:
Review question / Objective: Population: maintenance hemodialysis patients. Intervention: exercise therapy (resistance exercise； aerobic exercise； resistance combined aerobic exercise； muscle relaxation training； Baduanjin ). Comparison: simple routine nursing. Outcome: fatigue； sleep quality. Study design: randomized controlled trial. Eligibility criteria: Inclusion and exclusion criteria： RCT of study type exercise intervention in MHD patients' fatigue； Study subjects： MHD patients ≥18 years old, regardless of gender, nationality or race； The intervention measures were exercise therapy, incl
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography